iSign Solutions (ISGN) 10-K 2 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Apr. 02, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	iSign Solutions Inc.
Entity Central Index Key	727,634
Amendment Flag	false
Trading Symbol	ISGN
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		5,761,980

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 285	$ 389
Accounts receivable, net of allowance of $1 and $63 at December 31, 2017 and 2016, respectively	45	137
Prepaid expenses and other current assets	28	56
Total current assets	358	582
Property and equipment, net	13	20
Intangible assets, net		269
Other assets	17	17
Total assets	388	888
Current liabilities:
Accounts payable	1,289	1,368
Short-term debt, net	1,458
Accrued compensation	201	257
Other accrued liabilities	740	505
Deferred revenue	310	258
Short-term capital lease	4	4
Total current liabilities	4,002	2,392
Long-term debt, net		707
Deferred revenue long-term	175	315
Long-term capital lease	6	9
Other long-term liabilities	7	13
Total liabilities	4,190	3,436
Commitments and contingencies (Note 8)
Equity (deficit):
Common stock, $0.01 par value; 2,000,000 shares authorized; 5,760 and 5,760 shares issued and outstanding at December 31, 2017 and 2016, respectively	58	58
Treasury shares, 5 at December 31, 2017 and December 31, 2016, respectively	(325)	(325)
Additional paid-in-capital	129,027	128,884
Accumulated deficit	(132,562)	(130,615)
Accumulated other comprehensive loss		(14)
Total iSign stockholders' deficit	(3,802)	(2,012)
Non-controlling interest		(536)
Total deficit	(3,802)	(2,548)
Total liabilities and deficit	$ 388	$ 888

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance	$ 1	$ 63
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000	2,000,000
Common stock, shares issued	5,760	5,760
Common stock, shares outstanding	5,760	5,760
Treasury shares	5	5

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Product	$ 322	$ 325
Maintenance	691	740
Total revenue	1,013	1,065
Cost of sales:
Product	13	78
Maintenance	113	308
Research and development	1,135	1,322
Sales and marketing	188	406
General and administrative	1,122	2,160
Total operating costs and expenses	2,571	4,274
Loss from operations	(1,558)	(3,209)
Other income (expense), net	67	(12)
Gain on sale of intangible assets	303
Write-off of interest in Chinese joint venture	(550)
Interest expense:
Related party	(26)	(103)
Other	(86)	(115)
Amortization of debt discount:
Related party	(27)	(87)
Other	(70)	(303)
Gain on derivative liability		330
Net loss	(1,947)	(3,499)
Accretion of beneficial conversion feature:
Related party		(115)
Other		(130)
Preferred stock dividends:
Related party		(646)
Other		(667)
Income tax expense
Net loss before non-controlling interest	(1,947)	(5,057)
Net loss attributable to non-controlling interest
Net loss attributable to common stockholders	$ (1,947)	$ (5,057)
Basic and diluted loss per common share	$ (0.34)	$ (1.91)
Weighted average common shares outstanding, basic and diluted	5,760	2,644

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Comprehensive Loss [Abstract]
Net loss:	$ (1,947)	$ (3,499)
Other comprehensive income, net of tax
Foreign currency translation adjustment, net
Total comprehensive loss	$ (1,947)	$ (3,499)

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Series A-1 Preferred Shares	Series B Preferred Shares	Series C Preferred Shares	Series D-1 Preferred Shares	Series D-2 Preferred Shares	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Non-Controlling Interest	Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2015	$ (1,870)	$ 947	$ 11,653	$ 6,069	$ 6,866	$ 5,272	$ 2	$ (325)	$ 95,312	$ (127,116)	$ (536)	$ (14)
Beginning balance, shares at Dec. 31, 2015		947	13,523	5,491	8,077	6,321	187
Stock-based employee compensation	164								164
Preferred share dividends, paid in kind		$ 29	$ 519	$ 211	$ 309	$ 245			(1,313)
Preferred share dividends, paid in kind, shares		29	519	211	309	245
Beneficial conversion feature on preferred shares dividends issued in kind		$ (3)	$ (73)	$ (39)	$ (78)	$ (52)			245
Accretion of beneficial conversion feature on preferred shares dividends issued in kind		3	73	39	78	52			(245)
Common shares and warrants issued in a private placement, net of $780 offering costs	424						$ 7		417
Common shares and warrants issued in a private placement, net of $780 offering costs, shares							690
Common shares issued on exchange of unsecured debt	1,181						$ 7		1,181
Common shares issued on exchange of unsecured debt, shares							683
Common shares issued on exchange of deferred compensation	498						$ 3		495
Common shares issued on exchange of deferred compensation, shares							286
Conversion of Preferred Shares into Common Stock		$ (976)	(12,172)	(6,280)	(7,175)	$ (5,517)	$ 36		32,084
Conversion of Preferred Shares into Common Stock, shares		(976)					3,650
Conversion of convertible notes into Common Stock	240						$ 3		237
Conversion of convertible notes into Common Stock, shares							264
Proceeds allocated to warrants issued in connection with convertible notes	204								204
Beneficial Conversion Feature on convertible notes	103								103
Net loss	(3,499)									(3,499)
Ending balance at Dec. 31, 2016	(2,548)						$ 58	(325)	128,884	(130,615)	(536)	(14)
Ending balance, shares at Dec. 31, 2016							5,760
Stock-based employee compensation	143								143
Write-off of interest in Chinese joint venture	550										536	14
Net loss	(1,947)									(1,947)
Ending balance at Dec. 31, 2017	$ (3,802)						$ 58	$ (325)	$ 129,027	$ (132,562)
Ending balance, shares at Dec. 31, 2017							5,760

Consolidated Statement of Chan7

Consolidated Statement of Changes in Equity Deficit (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Statement of Stockholders' Equity [Abstract]
Net of offering costs	$ 780

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (1,947)	$ (3,499)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	277	362
Amortization of debt discount	97	390
Stock-based employee compensation	143	164
Gain on derivative liability		(330)
Gain on sale of intangible assets	(303)
Write-off of interest in Chinese joint venture	550
Changes in operating assets and liabilities:
Accounts receivable, net	92	(43)
Prepaid expenses and other current assets	28	316
Accounts payable	(79)	581
Accrued compensation	(56)	(6)
Other accrued liabilities	227	510
Deferred revenue	(88)	(266)
Net cash used in operating activities	(1,059)	(1,821)
Cash flows from investing activities:
Acquisition of property and equipment	(3)
Proceeds from the sale of intangible assets	303
Net cash provided by investing activities	300
Cash flows from financing activities:
Proceeds from advances on accounts receivable	120
Proceeds from issuance of short-term debt		440
Proceeds from issuance of long-term debt	655	700
Proceeds from issuance of common stock and warrants, net of issuance costs of $780		424
Payment of short-term debt		(200)
Payment of advances from accounts receivable	(120)
Net cash provided by financing activities	655	1,364
Net decrease in cash and cash equivalents	(104)	(457)
Cash and cash equivalents at beginning of period	389	846
Cash and cash equivalents at end of period	285	389
Supplementary disclosure of cash flow information
Interest paid	9	62
Non-cash financing and investing transactions
Acquisition of property and equipment through capital lease		15
Conversion of convertible notes plus accrued interest into 947 shares of Common Stock		1,428
Conversion of deferred compensation plus accrued interest into 286 shares of Common Stock		498
Exchange of long-term unsecured convertible promissory notes for long-term unsecured promissory notes	200
Exchange of long-term unsecured convertible promissory notes for long-term secured promissory notes	250
Dividends on preferred shares		1,313
Conversion of preferred stock into Common Stock		32,119
Accretion of beneficial conversion feature on preferred share dividends		245
Beneficial conversion feature on convertible notes		103
Exchange of $200 of demand notes for long-term unsecured convertible notes		200
Warrants issued in connection with convertible notes		$ 204

Consolidated Statements of Cas9

Consolidated Statements of Cash Flows (Parenthetical) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)shares
Issuance of common stock and warrants, net of issuance costs | $	$ 780
Conversion of convertible notes plus accrued interest in common stock, shares | shares	947
Conversion of deferred compensation plus accrued interest in common stock, shares | shares	286
Exchange amount of demand notes for long-term unsecured convertible notes | $	$ 200

Nature of Business, Basis of Pr

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies	1. Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies: The Company: The Company is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, biometric authentication and simple-to-complex workflow management. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. The Company’s products and services result in legally binding transactions that are compliant with applicable laws and regulations and that can provide a higher level of security than paper-based processes. The Company has been a leading supplier of enterprise software solutions within the financial services and insurance industries and has delivered significant expense reduction by enabling complete document and workflow automation and the resulting reduction in mailing, scanning, filing and other costs related to the use of paper. The Company’s research and development activities have given rise to numerous technologies and products. The Company’s core DTM technologies include various forms of electronic signatures, such as handwritten biometric, click-to-sign and others, as well as signature verification, cryptography and the logging of audit trails to show signers’ intent. These technologies can enable secure, legal and regulatory compliant electronic transactions that can enhance customer experience at a fraction of the time and cost required by traditional, paper-based processes. The Company’s products include SignatureOne ® ™ ® ® Going concern and management plans: The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Except for 2004, the Company has incurred significant losses since its inception and, at December 31, 2017, the Company’s accumulated deficit was $132,562. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of December 31, 2017, the Company’s cash balance was $285. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis of consolidation: The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America, and include the accounts of iSign Solutions Inc. and its 90%-owned Joint Venture in the People’s Republic of China. All inter-company accounts and transactions have been eliminated. All amounts shown in the accompanying consolidated financial statements are in thousands of dollars except per share amounts. Use of estimates: The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. Fair value measures: Fair value is the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market for the asset or liability in an ordinary transaction between market participants on the measurement date. Our policy on fair value measures requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The policy prioritizes the inputs into three levels that may be used to measure fair value: Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s assets and liabilities measured at fair value, whether recurring or non-recurring, at December 31, 2017 and December 31, 2016, and the fair value calculation input hierarchy level that we have determined applies to each asset and liability category. Fair Value of Financial Instruments: The Company carries financial instruments on the consolidated balance sheet at the fair value of the instruments as of the consolidated balance sheet date. At the end of each period, management assesses the fair value of each instrument and adjusts the carrying value to reflect its assessment. At December 31, 2017 and December 31, 2016, the carrying values of accounts receivable and accounts payable approximated their fair values. Treasury Stock: Shares of Common Stock returned to, or repurchased by, the Company are recorded at cost and are included as a separate component of stockholders’ equity (deficit). Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account titled treasury stock. The equity accounts that were credited for the original share issuance (Common Stock, additional paid-in capital, etc.) remain intact. When the treasury shares are reissued, proceeds in excess of cost are credited to additional paid-in capital. Any deficiency is charged to accumulated deficit (unless additional paid-in capital from previous treasury share transactions exists, in which case the deficiency is charged to that account, with any excess charged to accumulated deficit). Derivatives: The Company, from time to time, enters into transactions which contain conversion privileges, the settlement of which may entitle the holder or the Company to settle the obligation(s) by issuance of Company securities. The Company applies a two-step model in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the scope exception. The fair value of each derivative is estimated each reporting period. The conversion option included within the unsecured convertible promissory notes is accounted for as a derivative liability at its estimated fair value. The derivative is subject to re-measurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income, in the consolidated statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the conversion or maturity of the unsecured convertible promissory note purchase agreements. Cash and cash equivalents: The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at December 31, consisted of the following: 2017 2016 Cash in bank $ 285 $ 389 Cash and cash equivalents $ 285 $ 389 Concentrations of credit risk: Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company maintains its cash and cash equivalents with various financial institutions. This diversification of risk is consistent with Company policy to maintain liquidity, and mitigate risk of loss as to principal. To date, accounts receivable have been derived principally from revenue earned from end users, manufacturers, and distributors of computer products in North America. The Company performs periodic credit evaluations of its customers, and does not require collateral. The Company maintains reserves for potential credit losses; historically, such losses have been within management’s expectations. The allowance for doubtful accounts is based on the Company’s assessment of the collectability of specific customer accounts and an assessment of international, political and economic risk as well as the aging of the accounts receivable. If there is a change in actual defaults from the Company’s historical experience, the Company’s estimates of recoverability of amounts due could be affected and the Company will adjust the allowance accordingly. Deferred financing costs: Deferred financing costs include costs paid in cash, such as professional fees and commissions. The costs associated with equity financings, such as in the sale Common or Preferred Stock, are netted against the proceeds of the offering. In the case of note financings, costs are amortized to interest expense over the life of the notes or upon early payment using the effective interest method. There were no financing costs amortized to interest expense for the years ended December 31, 2017 and 2016, respectively. Property and equipment, net: Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, ranging from three to five years. Leasehold improvements are amortized over their estimated useful lives, not to exceed the term of the related lease. The cost of additions and improvements is capitalized while maintenance and repairs are charged to expense as incurred. Depreciation expense was $8 and $40 for the years ended December 31, 2017 and 2016, respectively. Intangible Assets: Intangible assets are stated at cost less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets, ranging from five to seventeen years. Amortization expense was $269 and $322 for the years ended December 31, 2017 and 2016, respectively. The intangible assets have been fully amortized as of December 31, 2017. Long-lived assets: The Company evaluates the recoverability of its long-lived assets, including intangible assets at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. No such impairment charge was recorded during the years ended December 31, 2017 and 2016, respectively. Share-based payment: Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that ultimately expected to vest during the period. The fair value of share-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model Forfeitures share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and it is assumed no dividends will be declared. The estimated fair value of share-based compensation awards to employees is amortized over the vesting period of the options. Revenue recognition: The Company recognizes revenue from sales of software products upon shipment, provided that persuasive evidence of an arrangement exists, the fee is fixed and determinable, collection is determined to be probable, all non-recurring engineering work necessary to enable the Company’s product to function within the customer’s application has been completed and the Company’s product has been delivered according to specifications. Revenue from service subscriptions is recognized as costs are incurred or over the service period, whichever is longer. Software license agreements may contain multiple elements, including upgrades and enhancements, products deliverable on a when and if available basis and post- contract support. Revenue from software license agreements is recognized upon delivery of the software, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all nonrecurring engineering work necessary to enable the Company’s products to function within the customer’s application has been completed, and the Company has delivered its product according to specifications. For arrangements with multiple deliverables, the Company allocates consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices which is determined using vendor specific objective evidence. Maintenance revenue is recorded for post-contract support and upgrades or enhancements, which is paid for in addition to license fees, and is recognized as costs are incurred or over the support period whichever is longer. For undelivered elements where vendor specific objective evidence does not exist, revenue is deferred and subsequently recognized when delivery has occurred and when vendor specific evidence has been determined. Research and development: Research and development costs are charged to expense as incurred. Marketing: The Company expenses advertising (marketing) costs as incurred. These expenses are outbound marketing expenses associated with participation in industry events, related sales collateral and email campaigns aimed at generating customer participation in webinars. The expense for the years ended December 31, 2017 and 2016 was $0 and $1, respectively. Net loss per share: The Company calculates net loss per share under the provisions of the relevant accounting guidance. That guidance requires the disclosure of both basic net loss per share, which is based on the weighted average number of shares outstanding, and diluted loss per share, which is based on the weighted average number of shares and dilutive potential shares outstanding. The number of shares of Common Stock subject to outstanding options and shares issuable upon exercise of warrants excluded from the calculation of loss per share as their inclusion would be anti-dilutive are as follows: December 31, December 31, Common Stock subject to outstanding options 736 71 Common Stock subject to outstanding warrants 1,878 1,882 The Company considers the functional currency of the Joint Venture, CICC, to be the local currency of China, which is the Renminbi (“RMB”) and, accordingly, gains and losses from the translation of the local foreign currency financial statements are included as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. Foreign currency assets and liabilities are translated into U.S. dollars at the end-of-period exchange rates except for long-term assets and liabilities, which are translated at historical exchange rates. Revenue and expenses are translated at the average exchange rates in effect during each period except for those expenses related to consolidated balance sheet amounts which are translated at historical exchange rates. Net foreign currency transaction gains and losses are included in interest and other income, net in the accompanying consolidated statements of operations. Foreign currency transaction gains and losses in 2017 and 2016 were insignificant. Income taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts and for tax loss and credit carry-forwards. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized. Foreign currency translation: There have been no unrecognized tax benefits and, accordingly, there has been no effect on the Company’s financial condition or results of operations. The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to U.S. federal tax examinations for years before 2008, and state tax examinations for years before 2007. Management is in the process of reviewing the effects on the Company’s unrecognized tax positions in response to the changes the federal tax rates adopted in December of 2017. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Recently issued accounting pronouncement: In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): “Recognition and Measurement of Financial Assets and Financial Liabilities.” The new guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for the Company in the first quarter of fiscal 2018, with early adoption permitted under limited circumstances. The adoption of this guidance will not have a material impact on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02. “Leases.” ASU 2016-02 requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the effect the Standard will have on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU 2016-02 requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the effect the Standard will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which makes a number of changes meant to simplify and improve accounting for share-based payments. The company has adopted ASU 2016-09 as of January 1, 2017. The adoption had no impact on the Company’s consolidated financial statements. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), “Revenue from Contracts with Customers.” ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition” (Topic 605), and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. As currently issued, the standard is effective beginning in the first quarter of fiscal year 2018. We adopted the new standard effective January 1, 2018 utilizing the modified retrospective method. We finalized our analysis and the adoption of this guidance will not have a material impact on our consolidated financial statements and our internal controls over financial reporting.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2017
Concentrations [Abstract]
Concentrations	2. Concentrations: The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue for the 2017 2016 2017 2016 Customer #1 – – 13 % 13 % Customer #2 – – 14 % 13 % Customer #3 – 55 % 30 % 23 % Customer #4 44 % 11 % – – Customer #5 54 % 25 % – – Total concentration 98 % 91 % 57 % 49 % The following table summarizes sales concentrations: December 31, December 31, Sales within the United States 88 % 88 % Sales outside of the United States 12 % 12 % Total 100 % 100 %

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property and Equipment [Abstract]
Property and equipment	3. Property and equipment: Property and equipment, net at December 31, consists of the following: 2017 2016 Machinery and equipment $ 59 $ 1,235 Office furniture and fixtures 25 435 Leasehold improvements – 35 Purchased software 1 323 85 2,028 Less accumulated depreciation and amortization (72 ) (2,008 ) $ 13 $ 20

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2017
Intangible Assets [Abstract]
Intangible assets	4. Intangible assets: Intangible assets, net consists of the following at December 31: Weighted 2017 2016 Technology – $ 6,745 $ 6,745 Less accumulated amortization (6,745 ) (6,476 ) $ – $ 269 The nature of the underlying technology of our intangible assets can be referred to as ’‘transaction-enabling,’’ ’‘digital authentication’’ and ’‘business process work flow.’’ This technology includes various forms of electronic signature methods, such as handwritten, biometric, click-to-sign and others, as well as technologies related to signature verification, authentication, cryptography and the logging of audit trails to prove signers’ intent. Our technologies enable the appending of secure, legal and regulatory compliant electronic signatures coupled with an enhanced user experience at a fraction of the time and cost required by traditional, paper-based processes for signature capture. The Company does not foresee any effects of obsolescence or significant competitive pressure on its current or future products, anticipates increasing demand for products utilizing its technology, and believes that the current markets for its products based on technology will remain constant or will grow over the remaining useful lives assigned to its intangible assets because of business environments encouraging the use of electronic signatures.

Chinese Joint Venture (Non-Cont

Chinese Joint Venture (Non-Controlling Interest)	12 Months Ended
	Dec. 31, 2017
Chinese Joint Venture (Non-Controlling Interest) [Abstract]
Chinese Joint Venture (Non-Controlling Interest)	5. Chinese Joint Venture (Non-Controlling Interest): The Company currently owns 90% of a joint venture (the “Joint Venture”) with the Jiangsu Hongtu Electronics Group, a provincial agency of the People’s Republic of China. The Joint Venture’s business license expires October 18, 2043. There were no operations in 2017 or 2016. The Joint Venture had no revenue for the years ended December 31, 2017 and 2016, respectively. It had no long-lived assets as of December 31, 2017 and 2016. The Company recorded a non-cash charge to income of $550 related to the write-off of the interest in the joint venture.

Other Accrued Liabilities

Other Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Other Accrued Liabilities [Abstract]
Other accrued liabilities	6. Other accrued liabilities: The Company records liabilities based on reasonable estimates for expenses, or payables that are known or estimated including deposits, taxes, rents and services. The estimates are for current liabilities that should be extinguished within one year. The Company had the following other accrued liabilities at December 31: 2017 2016 Accrued professional services $ 15 $ 38 Rents 3 – Management fees 440 316 Accrued interest 129 27 Delaware Franchise tax 129 77 Other 24 47 Total $ 740 $ 505

Debt

Debt	12 Months Ended
	Dec. 31, 2017
Debt [Abstract]
Debt	7. Debt: Advances: In February 2017, the Company received, from investors and affiliates of the Company, advances aggregating $120 in cash against certain accounts receivable of the Company. Upon collection of an invoice, the Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee. The receivables were collected and the advances were repaid in March 2017, along with $6 in advance fees per the agreement. The advance fees were recorded as interest expense in the quarter ended March 31, 2017. Notes payable In November 2016, the Company issued long-term unsecured convertible promissory notes to investors and affiliates of the Company aggregating $700 in cash. The Company also issued the same long-term notes to affiliates in exchange for an aggregate of $200 in demand notes that had been issued earlier in September and October of 2016. The long-term notes are mandatorily convertible into Common Stock at a conversion rate of the lesser of $0.50 per share (initially, $1.30 per share and subsequently reduced in connection with the May 2017 described below) or the price per share of Common Stock, upon closing a new debt and or equity financing of at least $1,000 in aggregate proceeds. The notes bear interest at the rate of 6% per annum and are due December 31, 2018. The Company issued warrants to purchase 277 shares of Common Stock in connection with these long-term notes. The Company ascribed a value of $204 to the 277 warrants and recorded a discount to the long-term notes and a corresponding amount to additional paid-in capital. The discount is being amortized using the effective interest method over the term of the notes. Notes payable: In May 2017, the Company issued secured convertible promissory notes to investors and affiliates of the Company aggregating $505 in cash. In addition, certain investors and affiliates of the Company that had taken part in the November 2016 financing discussed above, and that also participated in the May 2017 financing, exchanged $450 of unsecured convertible promissory notes received in the November 2016 financing for $250 secured notes with the same terms as the notes issued in the May 2017 financing and $200 in unsecured notes with the same terms as the November 2016 financing discussed above. The secured notes are mandatorily convertible into Common Stock at a conversion rate of the lesser of $0.50 per share or the price per share of Common Stock, upon closing a new financing of at least $1,000 in aggregate proceeds. The secured notes bear interest at the rate of 10% per annum, are due December 31, 2018 and are secured by an interest in all the Company’s rights, title and interest in, to and under its intellectual property. Should the secured notes remain outstanding following the maturity date an additional 30% of the note’s principal amount shall become due and payable. In December 2017, the Company issued additional secured convertible promissory notes to investors and affiliates of the Company aggregating $150 in cash. The secured notes have substantially the same terms as the secured notes issued in the May 2017 financing. The Company used the funds received from the above financing for working capital and general corporate purposes. During the twelve months ended December 31, 2017, the Company accrued $112 of interest expense, $100 associated with the notes, of which $26 was to related parties and $74 was to other investors. The Company recorded $97 and $390 in debt discount amortization for the twelve months ended December 31, 2017 and 2016, respectively.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity (Deficit) [Abstract]
Stockholders' equity (deficit)	8. Stockholders’ equity (deficit): Common stock options: At December 31, 2017, the Company has two stock-based employee compensation plans, the 2009 Stock Compensation Plan, and the 2011 Stock Compensation Plan. The Company may also grant options to employees, directors and consultants outside of the 2009 and 2011 plans under individual plans. Information with respect to the Stock Compensation Plans at December 31, 2017 is as follows: 2009 Stock Compensation Plan 2011 Stock Compensation Plan Shares authorized for issuance 7,000 750,000 Option vesting period Quarterly over 3 years Immediate/Quarterly over 3 years Date adopted by shareholders − November 2011 Option term 7 Years 7 Years Options outstanding − 736 Options exercisable − 95 Weighted average exercise price $ − $3.65 Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black Scholes Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. There were no stock options granted during 2016. The fair value calculations are based on the following assumptions: Year Ended Year Ended Risk free interest rate 1.56% – 1.79% N/A Expected life (years) 5.30 – 6.80 N/A Expected volatility 184.14% – 212.15% N/A Expected dividends None N/A Estimated average forfeiture rate 5.87% N/A The following table summarizes the allocation of stock-based compensation expense for the years ended December 31, 2017 and 2016. There were no stock options exercised during the years ended December 31, 2017 and 2016. December 31, December 31, Research and development $ 60 $ 56 Sales and marketing – 15 General and administrative 51 71 Director options and consultants 32 22 Stock-based compensation expense included in operating expenses $ 143 $ 164 As of December 31, 2017, there was $142 of total unrecognized compensation cost related to non-vested share-based compensation arrangements. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.4 years. The cash flows from tax benefits for deductions in excess of the compensation costs recognized for share-based payment awards would be classified as financing cash flows. Due to the Company’s loss position, there were no such tax benefits during the year ended December 31, 2017. The summary activity for the Company’s 2011 Stock Compensation Plans is as follows: December 31, 2017 December 31, 2016 Shares Weighted Aggregate Intrinsic Weighted Average Shares Weighted Aggregate Weighted Outstanding at beginning of period 71 $ 45.21 $ – 82 $ 45.35 $ – Granted 899 $ 0.50 $ – – $ – $ – Forfeited/ Cancelled (234 ) $ 4.24 $ – (11 ) $ 46.23 $ – Outstanding at period end 736 $ 3.65 $ – 6.34 71 $ 45.21 $ – 3.07 Options vested and exercisable at period end 95 $ 24.41 $ – 4.12 60 $ 48.78 $ – 2.79 Weighted average grant-date fair value of options granted during the period $ 0.33 $ – The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2017: Options Outstanding Options Exercisable Range of Exercise Prices Options Weighted Weighted Number Weighted $0.01 -$25.00 687 6.66 $ 0.67 47 $ 0.90 $25 – $625 49 2.01 $ 46.62 48 $ 47.19 736 6.34 $ 3.65 95 $ 24.41 A summary of the status of the Company’s non-vested shares as of December 31, 2017 is as follows: Non-vested Shares Shares Weighted Average Non-vested at January 1, 2017 11 $ 23.01 Granted 899 $ 0.50 Canceled/Forfeited (234 ) $ 4.24 Vested (35 ) $ 24.65 Non-vested at December 31, 2017 641 $ 0.57 An employee or consultant desiring to exercise or convert his or her stock options must provide a signed notice of exercise to the Chief Financial Officer. Once the exercise is approved an issue order is sent to the Company’s transfer agent and by certificate or through other means of conveyance, the shares are delivered to the employee or consultant, generally within three business days. The Company expects to make additional option grants in future years. The options issued to employees and directors will be subject to the same provisions outlined above, which may have a material impact on the Company’s financial statements. Preferred Stock: All of the Company’s Preferred Stock was converted into shares of common stock on May 19, 2016. Information with respect to dividends issued on the Company’s Preferred stock for the year ended December 31, 2016 is as follows: Dividends Beneficial 2016 2016 Series A-1 $ 29 $ 3 Series B 519 73 Series C 211 39 Series D-1 309 78 Series D-2 245 52 Total $ 1,313 $ 245 Treasury Stock: In January 2012, the Company received 5 shares of Common Stock from Phoenix in settlement of a 16b claim brought by a Company stockholder against Phoenix, certain affiliates and the Company, as a nominal defendant. The Common Stock was valued at $325. In settlement of an indemnification claim brought by Phoenix in March 2012, resulting from the settlement of the 16b claim in January 2012, the Company issued to Phoenix 278 shares of Series C Preferred Stock valued at $417. The Company booked a $417 accretion amount for the beneficial conversion feature on the 278 shares of Series C Preferred Stock. Warrants: There were no warrants issued in 2017. There were no warrant exercises in 2017 and 2016. The summary of warrants issued in 2016 is as follows: December 31, 2016 Related Party Other Total Shares issuable under warrants issued in connection with the sale of Common Stock ─ 345 345 Shares issuable under warrants issued upon conversion of convertible notes and deferred compensation 586 619 1,205 Shares issuable under warrants issued with unsecured convertible notes 77 200 277 Total 663 1,164 1,827 A summary of the outstanding warrants is as follows: December 31, 2017 December 31, 2016 Shares Weighted Shares Weighted Outstanding at beginning of period 1,882 $ 2.52 206 $ 33.00 Issued – $ – 1,827 $ 2.18 Expired (4 ) $ 34.38 (151 ) $ 33.31 Outstanding at end of period 1,878 $ 2.46 1,882 $ 2.52 Exercisable at end of period 1,878 $ 2.46 1,882 $ 2.52 A summary of the status of the warrants outstanding as of December 31, 2017 is as follows: Number of Shares Outstanding and Exercisable Weighted Average Weighted Average Exercise 50 0.01 $ 15.63 1,551 2.18 $ 2.18 277 0.42 $ 1.63 1,878 1.86 $ 2.46 As of December 31, 2017, 2,614 shares of Common Stock were reserved for issuance upon exercise of outstanding options and warrants.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies: Lease commitments: In November 2016, the Company moved its principal facilities to San Jose, California, pursuant to a lease that expires in 2019. In addition to monthly rent, the facilities are subject to additional rental payments for utilities and other costs above the base amount. Facilities rent expense was approximately $109 and $202 in 2017 and 2016, respectively. Contractual obligations Total 2018 2019 Thereafter Operating lease commitments $ 189 $ 102 $ 87 $ – Capital lease commitments 14 6 6 2 Total $ 203 $ 108 $ 93 $ 2

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Income taxes	10. Income taxes: At December 31, 2017, the Company had net operating loss carryforwards of $70,731 for federal income tax purposes which will begin to expire in 2018 if unused. The Company had net operating loss carryforwards for state income tax purposes of approximately $35,982. These state net operating losses carryforwards will begin to expire in the year 2017 if unused. Deferred tax assets and liabilities at December 31 consist of the following: 2017 2016 Deferred tax assets: Net operating loss carry-forwards $ 17,359 $ 25,730 Accruals and reserves 51 141 Deferred revenue 143 228 Intangibles 490 821 Other, net 39 53 Fixed assets 13 22 Gross tax assets 18,095 26,995 Valuation allowance (18,095 ) (26,995 ) Net deferred tax assets $ – $ – The Company’s provision for income taxes differs from the amount computed by applying the statutory U.S. federal income tax rate to loss before taxes as follows for the years ended December 31, 2017 and December 31, 2016: 2017 2016 Income tax benefit at the federal statutory rate $ (661 ) $ (1,183 ) State income tax benefit (135 ) (203 ) NOL expiration 118 426 Prior year true-ups 15 – Permanent items and other 354 (27 ) Tax cuts and Jobs Act Rate Changes 9,090 – Change in valuation allowance (8,781 ) 987 Income tax expense $ ─ $ ─ A full valuation allowance has been established for the Company’s net deferred tax assets since the realization of such assets through the generation of future taxable income is uncertain. Current tax laws impose substantial restrictions on the utilization of net operating losses and credit carryforwards in the event of an “ownership change”, as defined by the Internal Revenue Code (IRC). If there should be an ownership change, the Company’s ability to utilize its carryforwards could be limited On November 20, 2015, the FASB issued Accounting Standards Update 2015-17, Balance Sheet Classification of Deferred Taxes. The ASU is part of the Board’s simplification initiative aimed at reducing complexity in accounting standards and requires companies to classify all deferred tax assets and liabilities, along with any related valuation allowance, as noncurrent on the balance sheet. The adoption of this guidance did not have a material impact on our consolidated financial statements. In December 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”) was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact the company, most notably a reduction of the U.S. corporate income tax rate from 34 percent to 21 percent for tax years beginning after December 31, 2017. The company measures deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. Accordingly, the company’s deferred tax assets and liabilities were remeasured to reflect the reduction in the U.S. corporate income tax rate from 34 percent to 21 percent, resulting in a $9.1 million decrease in net deferred tax assets for the year ended December 31, 2017 and a corresponding $9.1 million decrease in valuation allowance as of December 31, 2017.

Nature of Business, Basis of 20

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Going concern and management plans	Going concern and management plans: The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Except for 2004, the Company has incurred significant losses since its inception and, at December 31, 2017, the Company’s accumulated deficit was $132,562. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of December 31, 2017, the Company’s cash balance was $285. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis of consolidation	Basis of consolidation: The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America, and include the accounts of iSign Solutions Inc. and its 90%-owned Joint Venture in the People’s Republic of China. All inter-company accounts and transactions have been eliminated. All amounts shown in the accompanying consolidated financial statements are in thousands of dollars except per share amounts.
Use of estimates	Use of estimates: The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.
Fair value measures	Fair value measures: Fair value is the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market for the asset or liability in an ordinary transaction between market participants on the measurement date. Our policy on fair value measures requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The policy prioritizes the inputs into three levels that may be used to measure fair value: Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s assets and liabilities measured at fair value, whether recurring or non-recurring, at December 31, 2017 and December 31, 2016, and the fair value calculation input hierarchy level that we have determined applies to each asset and liability category.
Fair Value of Financial Instruments	Fair Value of Financial Instruments: The Company carries financial instruments on the consolidated balance sheet at the fair value of the instruments as of the consolidated balance sheet date. At the end of each period, management assesses the fair value of each instrument and adjusts the carrying value to reflect its assessment. At December 31, 2017 and December 31, 2016, the carrying values of accounts receivable and accounts payable approximated their fair values.
Treasury Stock	Treasury Stock: Shares of Common Stock returned to, or repurchased by, the Company are recorded at cost and are included as a separate component of stockholders’ equity (deficit). Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account titled treasury stock. The equity accounts that were credited for the original share issuance (Common Stock, additional paid-in capital, etc.) remain intact. When the treasury shares are reissued, proceeds in excess of cost are credited to additional paid-in capital. Any deficiency is charged to accumulated deficit (unless additional paid-in capital from previous treasury share transactions exists, in which case the deficiency is charged to that account, with any excess charged to accumulated deficit).
Derivatives	Derivatives: The Company, from time to time, enters into transactions which contain conversion privileges, the settlement of which may entitle the holder or the Company to settle the obligation(s) by issuance of Company securities. The Company applies a two-step model in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the scope exception. The fair value of each derivative is estimated each reporting period. The conversion option included within the unsecured convertible promissory notes is accounted for as a derivative liability at its estimated fair value. The derivative is subject to re-measurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income, in the consolidated statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the conversion or maturity of the unsecured convertible promissory note purchase agreements.
Cash and cash equivalents	Cash and cash equivalents: The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents. The Company’s cash and cash equivalents, at December 31, consisted of the following: 2017 2016 Cash in bank $ 285 $ 389 Cash and cash equivalents $ 285 $ 389
Concentrations of credit risk	Concentrations of credit risk: Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company maintains its cash and cash equivalents with various financial institutions. This diversification of risk is consistent with Company policy to maintain liquidity, and mitigate risk of loss as to principal. To date, accounts receivable have been derived principally from revenue earned from end users, manufacturers, and distributors of computer products in North America. The Company performs periodic credit evaluations of its customers, and does not require collateral. The Company maintains reserves for potential credit losses; historically, such losses have been within management’s expectations. The allowance for doubtful accounts is based on the Company’s assessment of the collectability of specific customer accounts and an assessment of international, political and economic risk as well as the aging of the accounts receivable. If there is a change in actual defaults from the Company’s historical experience, the Company’s estimates of recoverability of amounts due could be affected and the Company will adjust the allowance accordingly.
Deferred financing costs	Deferred financing costs: Deferred financing costs include costs paid in cash, such as professional fees and commissions. The costs associated with equity financings, such as in the sale Common or Preferred Stock, are netted against the proceeds of the offering. In the case of note financings, costs are amortized to interest expense over the life of the notes or upon early payment using the effective interest method. There were no financing costs amortized to interest expense for the years ended December 31, 2017 and 2016, respectively.
Property and equipment, net	Property and equipment, net: Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, ranging from three to five years. Leasehold improvements are amortized over their estimated useful lives, not to exceed the term of the related lease. The cost of additions and improvements is capitalized while maintenance and repairs are charged to expense as incurred. Depreciation expense was $8 and $40 for the years ended December 31, 2017 and 2016, respectively.
Intangible Assets	Intangible Assets: Intangible assets are stated at cost less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets, ranging from five to seventeen years. Amortization expense was $269 and $322 for the years ended December 31, 2017 and 2016, respectively. The intangible assets have been fully amortized as of December 31, 2017.
Long-lived assets	Long-lived assets: The Company evaluates the recoverability of its long-lived assets, including intangible assets at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. No such impairment charge was recorded during the years ended December 31, 2017 and 2016, respectively.
Share-based payment	Share-based payment: Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that is ultimately expected to vest during the period. The grant date fair value of share-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and it is assumed no dividends will be declared. The estimated fair value of share-based compensation awards to employees is amortized over the vesting period of the options.
Revenue recognition	Revenue recognition: The Company recognizes revenue from sales of software products upon shipment, provided that persuasive evidence of an arrangement exists, the fee is fixed and determinable, collection is determined to be probable, all non-recurring engineering work necessary to enable the Company’s product to function within the customer’s application has been completed and the Company’s product has been delivered according to specifications. Revenue from service subscriptions is recognized as costs are incurred or over the service period, whichever is longer. Software license agreements may contain multiple elements, including upgrades and enhancements, products deliverable on a when and if available basis and post- contract support. Revenue from software license agreements is recognized upon delivery of the software, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all nonrecurring engineering work necessary to enable the Company’s products to function within the customer’s application has been completed, and the Company has delivered its product according to specifications. For arrangements with multiple deliverables, the Company allocates consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices which is determined using vendor specific objective evidence. Maintenance revenue is recorded for post-contract support and upgrades or enhancements, which is paid for in addition to license fees, and is recognized as costs are incurred or over the support period whichever is longer. For undelivered elements where vendor specific objective evidence does not exist, revenue is deferred and subsequently recognized when delivery has occurred and when vendor specific evidence has been determined.
Research and development	Research and development: Research and development costs are charged to expense as incurred.
Marketing	Marketing: The Company expenses advertising (marketing) costs as incurred. These expenses are outbound marketing expenses associated with participation in industry events, related sales collateral and email campaigns aimed at generating customer participation in webinars. The expense for the years ended December 31, 2017 and 2016 was $0 and $1, respectively.
Net loss per share	Net loss per share: The Company calculates net loss per share under the provisions of the relevant accounting guidance. That guidance requires the disclosure of both basic net loss per share, which is based on the weighted average number of shares outstanding, and diluted loss per share, which is based on the weighted average number of shares and dilutive potential shares outstanding. The number of shares of Common Stock subject to outstanding options and shares issuable upon exercise of warrants excluded from the calculation of loss per share as their inclusion would be anti-dilutive are as follows: December 31, December 31, Common Stock subject to outstanding options 736 71 Common Stock subject to outstanding warrants 1,878 1,882 The Company considers the functional currency of the Joint Venture, CICC, to be the local currency of China, which is the Renminbi (“RMB”) and, accordingly, gains and losses from the translation of the local foreign currency financial statements are included as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. Foreign currency assets and liabilities are translated into U.S. dollars at the end-of-period exchange rates except for long-term assets and liabilities, which are translated at historical exchange rates. Revenue and expenses are translated at the average exchange rates in effect during each period except for those expenses related to consolidated balance sheet amounts which are translated at historical exchange rates. Net foreign currency transaction gains and losses are included in interest and other income, net in the accompanying consolidated statements of operations. Foreign currency transaction gains and losses in 2017 and 2016 were insignificant.
Income taxes	Income taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts and for tax loss and credit carry-forwards. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized.
Foreign currency translation	Foreign currency translation: There have been no unrecognized tax benefits and, accordingly, there has been no effect on the Company’s financial condition or results of operations. The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to U.S. federal tax examinations for years before 2008, and state tax examinations for years before 2007. Management is in the process of reviewing the effects on the Company’s unrecognized tax positions in response to the changes the federal tax rates adopted in December of 2017. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.
Recently issued accounting pronouncement	Recently issued accounting pronouncement: In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): “Recognition and Measurement of Financial Assets and Financial Liabilities.” The new guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for the Company in the first quarter of fiscal 2018, with early adoption permitted under limited circumstances. The adoption of this guidance will not have a material impact on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02. “Leases.” ASU 2016-02 requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the effect the Standard will have on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU 2016-02 requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the effect the Standard will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which makes a number of changes meant to simplify and improve accounting for share-based payments. The company has adopted ASU 2016-09 as of January 1, 2017. The adoption had no impact on the Company’s consolidated financial statements. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), “Revenue from Contracts with Customers.” ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition” (Topic 605), and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. As currently issued, the standard is effective beginning in the first quarter of fiscal year 2018. We adopted the new standard effective January 1, 2018 utilizing the modified retrospective method. We finalized our analysis and the adoption of this guidance will not have a material impact on our consolidated financial statements and our internal controls over financial reporting.

Nature of Business, Basis of 21

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Schedule of cash and cash equivalents	2017 2016 Cash in bank $ 285 $ 389 Cash and cash equivalents $ 285 $ 389
Schedule of antidilutive securities excluded from calculation of earnings per share	December 31, December 31, Common Stock subject to outstanding options 736 71 Common Stock subject to outstanding warrants 1,878 1,882

Concentrations (Tables)

Concentrations (Tables)	12 Months Ended
	Dec. 31, 2017
Concentrations [Abstract]
Summary of accounts receivable and revenue concentrations	Accounts Receivable Total Revenue for the 2017 2016 2017 2016 Customer #1 – – 13 % 13 % Customer #2 – – 14 % 13 % Customer #3 – 55 % 30 % 23 % Customer #4 44 % 11 % – – Customer #5 54 % 25 % – – Total concentration 98 % 91 % 57 % 49 %
Schedule of sales concentrations by geographical areas	December 31, December 31, Sales within the United States 88 % 88 % Sales outside of the United States 12 % 12 % Total 100 % 100 %

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property and Equipment [Abstract]
Schedule of property and equipment, net	2017 2016 Machinery and equipment $ 59 $ 1,235 Office furniture and fixtures 25 435 Leasehold improvements – 35 Purchased software 1 323 85 2,028 Less accumulated depreciation and amortization (72 ) (2,008 ) $ 13 $ 20

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Intangible Assets [Abstract]
Summary of intangible assets	Weighted 2017 2016 Technology – $ 6,745 $ 6,745 Less accumulated amortization (6,745 ) (6,476 ) $ – $ 269

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Other Accrued Liabilities [Abstract]
Schedule of other accrued liabilities	2017 2016 Accrued professional services $ 15 $ 38 Rents 3 – Management fees 440 316 Accrued interest 129 27 Delaware Franchise tax 129 77 Other 24 47 Total $ 740 $ 505

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity (Deficit) [Abstract]
Summary of stock compensation plans	2009 Stock Compensation Plan 2011 Stock Compensation Plan Shares authorized for issuance 7,000 750,000 Option vesting period Quarterly over 3 years Immediate/Quarterly over 3 years Date adopted by shareholders − November 2011 Option term 7 Years 7 Years Options outstanding − 736 Options exercisable − 95 Weighted average exercise price $ − $3.65
Schedule of fair value of stock-based compensation based on black scholes merton valuation model	Year Ended Year Ended Risk free interest rate 1.56% – 1.79% N/A Expected life (years) 5.30 – 6.80 N/A Expected volatility 184.14% – 212.15% N/A Expected dividends None N/A Estimated average forfeiture rate 5.87% N/A
Summary of stock-based compensation expense	December 31, December 31, Research and development $ 60 $ 56 Sales and marketing – 15 General and administrative 51 71 Director options and consultants 32 22 Stock-based compensation expense included in operating expenses $ 143 $ 164
Summary of option activity	December 31, 2017 December 31, 2016 Shares Weighted Aggregate Intrinsic Weighted Average Shares Weighted Aggregate Weighted Outstanding at beginning of period 71 $ 45.21 $ – 82 $ 45.35 $ – Granted 899 $ 0.50 $ – – $ – $ – Forfeited/ Cancelled (234 ) $ 4.24 $ – (11 ) $ 46.23 $ – Outstanding at period end 736 $ 3.65 $ – 6.34 71 $ 45.21 $ – 3.07 Options vested and exercisable at period end 95 $ 24.41 $ – 4.12 60 $ 48.78 $ – 2.79 Weighted average grant-date fair value of options granted during the period $ 0.33 $ –
Summary of significant ranges of outstanding and exercisable options	Options Outstanding Options Exercisable Range of Exercise Prices Options Weighted Weighted Number Weighted $0.01 -$25.00 687 6.66 $ 0.67 47 $ 0.90 $25 – $625 49 2.01 $ 46.62 48 $ 47.19 736 6.34 $ 3.65 95 $ 24.41
Summary of status of the Company's non-vested shares	Non-vested Shares Shares Weighted Average Non-vested at January 1, 2017 11 $ 23.01 Granted 899 $ 0.50 Canceled/Forfeited (234 ) $ 4.24 Vested (35 ) $ 24.65 Non-vested at December 31, 2017 641 $ 0.57
Summary of Information with respect to dividends issued on the company's preferred stock	Dividends Beneficial 2016 2016 Series A-1 $ 29 $ 3 Series B 519 73 Series C 211 39 Series D-1 309 78 Series D-2 245 52 Total $ 1,313 $ 245
Summary of warrants issued	December 31, 2016 Related Party Other Total Shares issuable under warrants issued in connection with the sale of Common Stock ─ 345 345 Shares issuable under warrants issued upon conversion of convertible notes and deferred compensation 586 619 1,205 Shares issuable under warrants issued with unsecured convertible notes 77 200 277 Total 663 1,164 1,827
Schedule of warrants outstanding	December 31, 2017 December 31, 2016 Shares Weighted Shares Weighted Outstanding at beginning of period 1,882 $ 2.52 206 $ 33.00 Issued – $ – 1,827 $ 2.18 Expired (4 ) $ 34.38 (151 ) $ 33.31 Outstanding at end of period 1,878 $ 2.46 1,882 $ 2.52 Exercisable at end of period 1,878 $ 2.46 1,882 $ 2.52
Summary of information warrants outstanding and exercisable	Number of Shares Outstanding and Exercisable Weighted Average Weighted Average Exercise 50 0.01 $ 15.63 1,551 2.18 $ 2.18 277 0.42 $ 1.63 1,878 1.86 $ 2.46

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies [Abstract]
Schedule of contractual obligations	Contractual obligations Total 2018 2019 Thereafter Operating lease commitments $ 189 $ 102 $ 87 $ ─ Capital lease commitments 14 6 6 2 Total $ 203 $ 108 $ 93 $ 2

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Schedule of deferred tax assets and liabilities	2017 2016 Deferred tax assets: Net operating loss carry-forwards $ 17,359 $ 25,730 Accruals and reserves 51 141 Deferred revenue 143 228 Intangibles 490 821 Other, net 39 53 Fixed assets 13 22 Gross tax assets 18,095 26,995 Valuation allowance (18,095 ) (26,995 ) Net deferred tax assets $ – $ –
Schedule of statutory U.S. federal income tax rate to loss before taxes	2017 2016 Income tax benefit at the federal statutory rate $ (661 ) $ (1,183 ) State income tax benefit (135 ) (203 ) NOL expiration 118 426 Prior year true-ups 15 – Permanent items and other 354 (27 ) Tax cuts and Jobs Act Rate Changes 9,090 – Change in valuation allowance (8,781 ) 987 Income tax expense $ ─ $ ─

Nature of Business, Basis of 29

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Cash in bank	$ 285	$ 389
Cash and cash equivalents	$ 285	$ 389	$ 846

Nature of Business, Basis of 30

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details 1) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares	1,878	1,756
Common Stock subject to outstanding options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares	736	71
Common Stock subject to outstanding warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares	1,878	1,882

Nature of Business, Basis of 31

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Textual)
Accumulated deficit	$ (132,562)	$ (130,615)
Cash balance	$ 285	389	$ 846
Ownership percentage	90.00%
Depreciation expense	$ 8	40
Amortization expense	269	322
Marketing expenses	$ 0	$ 1

Concentrations (Details)

Concentrations (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounts Receivable [Member]
Concentration Risk [Line Items]
Total concentration	98.00%	91.00%
Accounts Receivable [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration		55.00%
Accounts Receivable [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration	44.00%	11.00%
Accounts Receivable [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration	54.00%	25.00%
Total Revenue [Member]
Concentration Risk [Line Items]
Total concentration	57.00%	49.00%
Total Revenue [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration	13.00%	13.00%
Total Revenue [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration	14.00%	13.00%
Total Revenue [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration	30.00%	23.00%
Total Revenue [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration
Total Revenue [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration

Concentrations (Details 1)

Concentrations (Details 1)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Concentration risk, percentage of total sales	100.00%	100.00%
Sales within the United States [Member] | United States [Member]
Concentration Risk [Line Items]
Concentration risk, percentage of total sales	88.00%	88.00%
Sales outside of the United States [Member] | United States [Member]
Concentration Risk [Line Items]
Concentration risk, percentage of total sales	12.00%	12.00%

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 85	$ 2,028
Less accumulated depreciation and amortization	(72)	(2,008)
Property and equipment, Net	13	20
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	59	1,235
Office furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	25	435
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross		35
Purchased software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 1	$ 323

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Technology	$ 6,745	$ 6,745
Less accumulated amortization	(6,745)	(6,476)
Intangible assets, net		$ 269
Weighted Average Amortization Period	0 years	0 years

Chinese Joint Venture (Non-Co36

Chinese Joint Venture (Non-Controlling Interest) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Chinese Joint Venture (Non-Controlling Interest) (Textual)
Joint venture ownership percentage	90.00%
Joint venture license expire date, description	The Joint Venture's business license expires October 18, 2043.
Write-off of interest in joint venture	$ 550

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Accrued Liabilities [Abstract]
Accrued professional services	$ 15	$ 38
Rents	3
Management fees	440	316
Accrued interest	129	27
Delaware Franchise tax	129	77
Other	24	47
Total	$ 740	$ 505

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					12 Months Ended
	May 31, 2017	Feb. 28, 2017	Nov. 30, 2016	Oct. 31, 2016	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Debt (Textual)
Debt discount amortization						$ 97	$ 390
Warrants and recorded a discount to the long-term notes							240
Proceeds from issuance of long-term notes						655	700
Exchange of demand notes for long-term unsecured convertible notes							103
Aggregate cash						285	$ 389
Accrued interest expense						112
Notes issued						100
Due from related parties						26
Debt [Member]
Debt (Textual)
Aggregating amount of debt		$ 120
Advance fees						6
Description of advance fee		The Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee.
Investors and Affiliates [Member]
Debt (Textual)
Aggregate cash						150
Due from related parties						$ 74
Unsecured convertible promissory notes [Member] | Investors and Affiliates [Member]
Debt (Textual)
Warrants issued to purchase of common stock			277
Proceeds from issuance of long-term notes	$ 505		$ 700
Description of replacement notes	Should the secured notes remain outstanding following the maturity date an additional 30% of the note's principal amount shall become due and payable.
Unsecured convertible promissory notes received	$ 450
Demand promissory notes [Member] | Investors and Affiliates [Member]
Debt (Textual)
Exchange of demand notes for long-term unsecured convertible notes				$ 200	$ 200
Notes Payable [Member]
Debt (Textual)
Conversion price	$ 1.30		$ 0.50
Proceeds of equity financing	$ 1,000		$ 1,000
Interest rate	10.00%		6.00%
Due date	Dec. 31, 2018		Dec. 31, 2018
Unsecured convertible promissory notes received	$ 250
Notes Payable [Member] | Minimum [Member]
Debt (Textual)
Warrants and recorded a discount to the long-term notes			$ 204
Notes Payable [Member] | Maximum [Member]
Debt (Textual)
Warrants and recorded a discount to the long-term notes			$ 277

Stockholders' Equity (Deficit39

Stockholders' Equity (Deficit) (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Information with respect to the Stock Compensation Plans
Option term	6 years 4 months 2 days
2009 Stock Compensation Plan [Member]
Information with respect to the Stock Compensation Plans
Shares authorized for issuance	7,000,000
Option vesting period	Quarterly over 3 years
Option term	7 years
Options outstanding
Options exercisable
Weighted average exercise price | $ / shares
2011 Stock Compensation Plan [Member]
Information with respect to the Stock Compensation Plans
Shares authorized for issuance	750,000,000
Option vesting period	Immediate/Quarterly over 3 years
Date adopted by shareholders	November 2,011
Option term	7 years
Options outstanding	736
Options exercisable	95,000
Weighted average exercise price | $ / shares	$ 3.65

Stockholders' Equity (Deficit40

Stockholders' Equity (Deficit) (Details 1)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of stock options granted based on fair value assumptions
Expected dividends
Estimated average forfeiture rate	5.87%
Minimum [Member]
Schedule of stock options granted based on fair value assumptions
Risk free interest rate	1.56%
Expected life (years)	5 years 3 months 19 days
Expected volatility	184.14%
Maximum [Member]
Schedule of stock options granted based on fair value assumptions
Risk free interest rate	1.79%
Expected life (years)	6 years 9 months 18 days
Expected volatility	212.15%

Stockholders' Equity (Deficit41

Stockholders' Equity (Deficit) (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense included in operating expenses	$ 143	$ 164
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense included in operating expenses	60	56
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense included in operating expenses		15
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense included in operating expenses	51	71
Director options and consultants [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense included in operating expenses	$ 32	$ 22

Stockholders' Equity (Deficit42

Stockholders' Equity (Deficit) (Details 3) - 2011 Stock Compensation Plans [Member] - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Shares, Outstanding, Beginning balance	71	82
Options Shares, Granted	899
Options Shares, Forfeited/ Cancelled	(234)	(11)
Options Shares, Outstanding, Ending balance	736	71
Options vested and exercisable at period end	95	60
Weighted average grant-date fair value of options granted during the period	$ 0.33
Weighted Average Exercise Price Per Share, Outstanding, Beginning balance	45.21	45.35
Weighted Average Exercise Price Per Share, Granted	0.50
Weighted Average Exercise Price Per Share, Forfeited or expired	4.24	46.23
Weighted Average Exercise Price Per Share, Outstanding, Ending balance	3.65	45.21
Weighted Average Exercise Price, Options vested and exercisable	$ 24.41	$ 48.78
Aggregate Intrinsic Value, Outstanding, Beginning balance
Aggregate Intrinsic Value, Granted
Aggregate Intrinsic Value, Forfeited/ Cancelled
Aggregate Intrinsic Value, Outstanding, Ending balance
Aggregate Intrinsic Value, Options vested and exercisable
Weighted Average Remaining Contractual Life, Outstanding	6 years 4 months 2 days	3 years 26 days
Weighted Average Remaining Contractual Life, Options vested and exercisable	4 years 1 month 13 days	2 years 9 months 14 days

Stockholders' Equity (Deficit43

Stockholders' Equity (Deficit) (Details 4) shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	736
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 years 4 months 2 days
Options Outstanding, Weighted Average Exercise Price	$ 3.65
Options Exercisable, Number Outstanding | shares	95
Options Exercisable, Weighted Average Exercise Price Per Share	$ 24.41
$0.01 - $25.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.01
Range of Exercise Prices, Upper Range Limit	$ 25
Options Outstanding, Number Outstanding | shares	687
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 years 7 months 28 days
Options Outstanding, Weighted Average Exercise Price	$ 0.67
Options Exercisable, Number Outstanding | shares	47
Options Exercisable, Weighted Average Exercise Price Per Share	$ 0.90
$25 - 625 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	25
Range of Exercise Prices, Upper Range Limit	$ 625
Options Outstanding, Number Outstanding | shares	49
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	2 years 4 days
Options Outstanding, Weighted Average Exercise Price	$ 46.62
Options Exercisable, Number Outstanding | shares	48
Options Exercisable, Weighted Average Exercise Price Per Share	$ 47.19

Stockholders' Equity (Deficit44

Stockholders' Equity (Deficit) (Details 5) shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Non-vested Shares
Non-vested, Beginning balance | shares	11
Granted | shares	899
Canceled/Forfeited | shares	(234)
Vested | shares	(35)
Non-vested, Shares, Ending balance | shares	641
Weighted Average Grant-Date Fair Value per share
Non-vested, Beginning balance | $ / shares	$ 23.01
Granted | $ / shares	0.50
Canceled/Forfeited | $ / shares	4.24
Vested | $ / shares	24.65
Non-vested, Ending balance | $ / shares	$ 0.57

Stockholders' Equity (Deficit45

Stockholders' Equity (Deficit) (Details 6) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Dividends Issued	$ 1,313
Beneficial Conversion Feature	245
Series A-1 [Member]
Dividends Issued	29
Beneficial Conversion Feature	3
Series B [Member]
Dividends Issued	519
Beneficial Conversion Feature	73
Series C [Member]
Dividends Issued	211
Beneficial Conversion Feature	39
Series D-1 [Member]
Dividends Issued	309
Beneficial Conversion Feature	78
Series D-2 [Member]
Dividends Issued	245
Beneficial Conversion Feature	$ 52

Stockholders' Equity (Deficit46

Stockholders' Equity (Deficit) (Details 7) shares in Thousands	12 Months Ended
	Dec. 31, 2016shares
Class of Warrant or Right [Line Items]
Shares issuable under warrants issued in connection with the sale of Common Stock	345
Shares issuable under warrants issued upon conversion of convertible notes and deferred compensation	1,205
Shares issuable under warrants issued with unsecured convertible notes	277
Total	1,827
Related Party [Member]
Class of Warrant or Right [Line Items]
Shares issuable under warrants issued in connection with the sale of Common Stock
Shares issuable under warrants issued upon conversion of convertible notes and deferred compensation	586
Shares issuable under warrants issued with unsecured convertible notes	77
Total	663
Other [Member]
Class of Warrant or Right [Line Items]
Shares issuable under warrants issued in connection with the sale of Common Stock	345
Shares issuable under warrants issued upon conversion of convertible notes and deferred compensation	619
Shares issuable under warrants issued with unsecured convertible notes	200
Total	1,164

Stockholders' Equity (Deficit47

Stockholders' Equity (Deficit) (Details 8) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares, Issued		1,827
Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares, Outstanding at beginning of period	1,882	206
Number of Shares, Issued		1,827
Number of Shares, Expired	(4)	(151)
Number of Shares, Outstanding at end of period	1,878	1,882
Number of Shares, Exercisable at end of period	1,878	1,882
Weighted Average Exercise Price per share, Outstanding at beginning of period	$ 2.52	$ 33
Weighted Average Exercise Price per share, Issued		2.18
Weighted Average Exercise Price per share, Expired	34.38	33.31
Weighted Average Exercise Price per share, Outstanding at end of period	2.46	2.52
Weighted Average Exercise Price per share, Exercisable at end of period	$ 2.46	$ 2.52

Stockholders' Equity (Deficit48

Stockholders' Equity (Deficit) (Details 9) - Warrants [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
50 [Member]
Class of Warrant or Right [Line Items]
Number of Shares Outstanding and Exercisable | shares	50
Weighted Average Remaining Life (in years)	4 days
Weighted Average Exercise Price per share | $ / shares	$ 15.63
1,551 [Member]
Class of Warrant or Right [Line Items]
Number of Shares Outstanding and Exercisable | shares	1,551
Weighted Average Remaining Life (in years)	2 years 2 months 5 days
Weighted Average Exercise Price per share | $ / shares	$ 2.18
277 [Member]
Class of Warrant or Right [Line Items]
Number of Shares Outstanding and Exercisable | shares	277
Weighted Average Remaining Life (in years)	5 months 1 day
Weighted Average Exercise Price per share | $ / shares	$ 1.63
1,878 [Member]
Class of Warrant or Right [Line Items]
Number of Shares Outstanding and Exercisable | shares	1,878
Weighted Average Remaining Life (in years)	1 year 10 months 10 days
Weighted Average Exercise Price per share | $ / shares	$ 2.46

Stockholders' Equity (Deficit49

Stockholders' Equity (Deficit) (Details Textual) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Dec. 31, 2017
Stockholders' Equity (Deficit) (Textual )
Unrecognized compensation cost		$ 142
Unrecognized compensation cost, weighted average period		1 year 4 months 24 days
Common stock issuance		2,614
Series C Preferred Stock [Member]
Stockholders' Equity (Deficit) (Textual )
Accretion amount	$ 417
Beneficial conversion feature	278
Phoenix [Member]
Stockholders' Equity (Deficit) (Textual )
Received shares value of common stock	$ 325
Received shares of common stock	5
Phoenix [Member] | Series C Preferred Stock [Member]
Stockholders' Equity (Deficit) (Textual )
Received shares value of common stock	$ 417
Received shares of common stock	278

Commitments and Contingencies50

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2017USD ($)
Operating lease commitments
2,018	$ 102
2,019	87
Thereafter
Total	189
Capital lease commitments
2,018	6
2,019	6
Thereafter	2
Total	14
Total
2,018	108
2,019	93
Thereafter	2
Total	$ 203

Commitments and Contingencies51

Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Lease, description	Expires in 2019.
Rent expense		$ 109	$ 202

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carry-forwards	$ 17,359	$ 25,730
Accruals and reserves	51	141
Deferred revenue	143	228
Intangibles	490	821
Other, net	39	53
Fixed assets	13	22
Gross tax assets	18,095	26,995
Valuation allowance	(18,095)	(26,995)
Net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Income tax benefit at the federal statutory rate	$ (661)	$ (1,183)
State income tax benefit	(135)	(203)
NOL expiration	118	426
Prior year true-ups	15
Permanent items and other	354	(27)
Tax cuts and Jobs Act Rate Changes	9,090
Change in valuation allowance	(8,781)	987
Income tax expense

Income Taxes (Details Textual)

Income Taxes (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Income Taxes (Textual)
Federal net operating loss carry-forward	$ 70,731
State net operating loss carry-forward	$ 35,982
Income tax, description	The Tax Cuts and Jobs Act (the "2017 Tax Act") was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact the company, most notably a reduction of the U.S. corporate income tax rate from 34 percent to 21 percent for tax years beginning after December 31, 2017. The company measures deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. Accordingly, the company's deferred tax assets and liabilities were remeasured to reflect the reduction in the U.S. corporate income tax rate from 34 percent to 21 percent, resulting in a $9.1 million decrease in net deferred tax assets for the year ended December 31, 2017 and a corresponding $9.1 million decrease in valuation allowance as of December 31, 2017.